Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as manufactures and distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
IPO Year: 2014
Exchange: NASDAQ
Website: amphastar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/5/2024 | $60.00 | Overweight | JP Morgan |
| 11/17/2023 | $63.00 | Neutral | BofA Securities |
| 7/25/2023 | $70.00 | Buy | Jefferies |
| 10/21/2022 | $36.00 | Buy | Jefferies |
| 7/29/2022 | $44.00 | Overweight | CapitalOne |
| 3/11/2022 | $28.00 → $35.00 | Overweight | Piper Sandler |
| 1/7/2022 | $21.00 → $28.00 | Neutral → Overweight | Piper Sandler |
144 - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
144 - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
144 - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)
144 - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
144 - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024.Third quarter HighlightsNet revenues of $191.2 million for the third quarterGAAP net income of $40.4 million, or $0.78 per share, for the third quarterAdjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI®
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and int
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024.Second Quarter HighlightsNet revenues of $182.4 million for the second quarterGAAP net income of $37.9 million, or $0.73 per share, for the second quarterAdjusted non-GAAP net income of $48.7 million, or $0.94 per share, for the second quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "As we finish another strong quarter, Amphastar has continued its impressive performance with solid sales
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conferenc
TROY, Mich., June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) as its "Stock to Study" and Medtronic PLC (NYSE:MDT) as its "Undervalued Stock" in the September 2024 issue for investors' informational and educational use. "With GameStop back in the headlines, the siren song of easy money has returned, luring the unschooled down treacherous paths. The National Association of Investors counsels everyday Americans seeking long term wealth to focus on fundamentals and learn to earn," said Ken Zendel, CEO of National Association of Investors Corp. (NAIC), the parent organiza
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 4, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that on June 3, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and int
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 22, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir® HFA (albuterol s
JP Morgan initiated coverage of Amphastar Pharmaceuticals with a rating of Overweight and set a new price target of $60.00
BofA Securities initiated coverage of Amphastar Pharmaceuticals with a rating of Neutral and set a new price target of $63.00
Jefferies resumed coverage of Amphastar Pharmaceuticals with a rating of Buy and set a new price target of $70.00
Jefferies resumed coverage of Amphastar Pharmaceuticals with a rating of Buy and set a new price target of $36.00
CapitalOne initiated coverage of Amphastar Pharmaceuticals with a rating of Overweight and set a new price target of $44.00
Piper Sandler reiterated coverage of Amphastar Pharmaceuticals with a rating of Overweight and set a new price target of $35.00 from $28.00 previously
Piper Sandler upgraded Amphastar Pharmaceuticals from Neutral to Overweight and set a new price target of $28.00 from $21.00 previously
Wells Fargo reiterated coverage of Amphastar Pharmaceuticals with a rating of Equal-Weight and set a new price target of $20.00 from $21.00 previously
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024.Third quarter HighlightsNet revenues of $191.2 million for the third quarterGAAP net income of $40.4 million, or $0.78 per share, for the third quarterAdjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI®
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and int
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024.Second Quarter HighlightsNet revenues of $182.4 million for the second quarterGAAP net income of $37.9 million, or $0.73 per share, for the second quarterAdjusted non-GAAP net income of $48.7 million, or $0.94 per share, for the second quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "As we finish another strong quarter, Amphastar has continued its impressive performance with solid sales
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 31, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conferenc
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 3, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and int
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the Bank of America Health Care Conference on Wednesday, May 15th, 2024 at 2:20 pm PDT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal pr
Reports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2024.First Quarter HighlightsNet revenues of $171.8 million for the first quarterGAAP net income of $43.2 million, or $0.81 per share, for the first quarterAdjusted non-GAAP net income of $55.3 million, or $1.04 per share, for the first quarterDr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar's strong first quarter results were led by BAQSIMI ® revenue growth of 22% over what Eli Lilly & Co
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 30, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2024 ended March 31, 2024, after the market closes on Wednesday, May 8, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference
Piper Sandler analyst David Amsellem reiterates Amphastar Pharma (NASDAQ:AMPH) with a Overweight and maintains $71 price target.
Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:AMPH) with a Hold.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that the U.S. Food and Drug Administration ("FDA") has granted approval for the Company's Abbreviated New Drug Application ("ANDA") for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir® HFA(albuterol sulfate) Inhalation Aerosol.
Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:AMPH) with a Hold.
Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.77 by 35.06 percent. The company reported quarterly sales of $171.800 million which missed the analyst consensus estimate of $174.713 million by 1.67 percent. This is a 22.70 percent increase over sales of $140.022 million the same period last year.
The Federal Trade Commission (FTC) is intensifying its efforts to challenge numerous pharmaceutical patent listings, aiming to facilitate the availability of more affordable alternatives to brand-name drugs, including blockbusters like Novo Nordisk A/S’s (NYSE:NVO) Ozempic and Victoza. What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as patent tactics drugmakers employ to hinder generic competition. At the center of the issue is the Orange Book, a Food and Drug Administration (FDA) publication containing patents relevant to brand-name pharmace
At the Needham Healthcare Conference, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) highlighted why they remain excited about Baqsimi, the inhaled glucagon product for severe hypoglycemia. Amphastar Pharmaceuticals develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products. Needham says the company still believes Baqsimi is the best glucagon product based on its expertise, which is difficult to genericize, and its IP that goes to 2036. Needham notes that the market opportunity for Baqsimi is promising because only a small fraction of insulin users currently receive a prescription for glucagon to manage emergency hypoglycemia.
Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:AMPH) with a Hold.
JP Morgan analyst Ekaterina Knyazkova initiates coverage on Amphastar Pharma (NASDAQ:AMPH) with a Overweight rating and announces Price Target of $60.
Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling
Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling
Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling
Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 03/07/2023. Application Category: NDA, Application Number: 208969, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for AMPHASTAR PHARMS INC's drug VASOPRESSIN (ORIG-1) with active ingredient VASOPRESSIN has changed to 'Approval' on 07/18/2022. Application Category: ANDA, Application Number: 211857, Application Classification:
Submission status for AMPHASTAR PHARMS INC's drug NEOSTIGMINE METHYLSULFATE (SUPPL-1) with active ingredient NEOSTIGMINE METHYLSULFATE has changed to 'Approval' on 05/19/2022. Application Category: ANDA, Application Number: 209933, Application Classification: Labeling
Submission status for AMPHASTAR PHARMS INC's drug GANIRELIX ACETATE (ORIG-1) with active ingredient GANIRELIX ACETATE has changed to 'Approval' on 04/07/2022. Application Category: ANDA, Application Number: 212613, Application Classification:
Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-32) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/14/2021. Application Category: NDA, Application Number: 016750, Application Classification: Labeling
For Immediate Release: December 28, 2020 Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low blood sugar), which may occur in patients with diabetes mellitus. The drug is also indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum (the first part of the small intestine beyo
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)
SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)